English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

137 Children affected with osteogenesis imperfecta (OI) have increased morbidity and mortality and no definite treatment has been found yet. Recurrent fractures and bone deformities are the main complications of this disease. Recent studies have shown the ability of intravenous pamidronate to prevent fractures, when given in a cyclical manner [1]. This treatment is being used currently to prevent recurrence of fractures in children with OI but the clinical experience with such therapy is greatly limited. In this brief communication, we report our experience in treating OI children with the intravenous pamidronate during the last 4 years.

Cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta